J. Tcheng

J. Carroll, G. Stone, C. Grines, 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Morbidity and Mortality Conference for Percutaneous Coronary Intervention

Sunil V. Rao, Manesh R Patel, J. Tcheng, 2017, Circulation. Cardiovascular quality and outcomes.

Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial.

J. Tcheng, J. Blankenship, K. Pieper, 2001, American Journal of Cardiology.

Primary Angioplasty

J. Tcheng, T. Watson, P. Ong, 2018, Springer Singapore.

Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.

S. Denardo, J. Tcheng, Keith E. Davis, 2005, American heart journal.

Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.

V. Hasselblad, R. Califf, G. Stone, 2004, American heart journal.

The benefit of abciximab in percutaneous coronary revascularization is not device-specific.

Deepak L. Bhatt, R. Califf, E. Topol, 2000, The American journal of cardiology.

Platelet and Thrombin Inhibitors as Adjuncts to Thrombolytic Therapy and Percutaneous Coronary Interventions: A Review

J. Tcheng, P. B. Amsterdam, 1997 .

Pursuit of the Optimal Antithrombotic Regimen for Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Who Undergo Subsequent Percutaneous Coronary Intervention.

S. Denardo, J. Tcheng, Keith E. Davis, 2019, The American journal of cardiology.

Primary Coronary Intervention: The Technical Approach

J. Tcheng, D. Cox, 2009 .

Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors.

J. J. Griffin, K. Harjai, G. Stone, 2007, The American journal of cardiology.

Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction.

J. J. Griffin, J. Carroll, G. Stone, 2004, The American journal of cardiology.

Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction.

G. Stone, C. Grines, R. Mehran, 2006, American heart journal.

Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials

Deepak L. Bhatt, E. Topol, A. Lincoff, 2003, Heart.

Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction

J. J. Griffin, J. Carroll, G. Stone, 2003, Circulation.

HRS White Paper on interoperability of data from cardiovascular implantable electronic devices (CIEDs).

T. Bunch, B. Wilkoff, J. Tcheng, 2019, Heart Rhythm.

Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art

H. Tan, R. Harrington, J. Tcheng, 2004, Journal of Thrombosis and Thrombolysis.

Long-term outcome following successful reopening of abrupt closure after coronary angioplasty.

R. Califf, C. Nelson, J. Tcheng, 1993, The American journal of cardiology.

Treatment of long coronary artery narrowings with long angioplasty balloon catheters.

M. Krucoff, J. Tcheng, R. Stack, 1993, The American journal of cardiology.

Outcome after prolonged balloon inflations of >20 minutes for initially unsuccessful percutaneous transluminal coronary angioplasty

J. Tcheng, R. Stack, H. Phillips, 1992 .

Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade: Findings of the ESPRIT Trial

Ing-Haan Lim, S. Srinivasan, J. Tcheng, 2008, Circulation. Cardiovascular interventions.

Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.

S. Denardo, J. Tcheng, Keith E. Davis, 2007, The American journal of cardiology.

Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial.

G. Levine, R. Harrington, J. Tcheng, 2003, Journal of the American College of Cardiology.

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.

R. Califf, E. Topol, A. Lincoff, 1995, American Journal of Cardiology.

Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.

W. Cantor, J. Tcheng, M. Madan, 2000, American heart journal.

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

R. Califf, E. Topol, K. Anderson, 1999, Circulation.

Final results of the ReoPro readministration registry.

M. Effron, A. Lincoff, J. Tcheng, 2004, The American journal of cardiology.

Efficacy of abciximab readministration in coronary intervention.

J. Tcheng, D. Kereiakes, M. Madan, 2000, The American journal of cardiology.

Safety of abciximab retreatment - Final clinical report of the ReoPro readministration registry (R-3)

M. Effron, A. Lincoff, J. Tcheng, 1998 .

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

David P Miller, R. Califf, E. Topol, 1997, JAMA.

Ultrasonographically guided manual compression of femoral artery injuries.

B. Carroll, E. Paulson, J. Bowie, 1995, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.

R. Califf, E. Topol, R. Harrington, 1998, Journal of the American College of Cardiology.

Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial.

J. J. Griffin, G. Stone, C. Grines, 2009, JACC. Cardiovascular interventions.

Color Doppler sonographic appearance of patent needle tracts after femoral arterial catheterization.

B. Carroll, E. Paulson, J. Tcheng, 1995, Radiology.

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.

J. Hochman, J. Tcheng, N. Kleiman, 2002, Journal of the American College of Cardiology.

Abciximab Readministration: Results of the ReoPro Readministration Registry

R. Jordan, M. Effron, A. Lincoff, 2001, Circulation.

Prasugrel versus Clopidogrel Antiplatelet Therapy after Acute Coronary Syndrome

S. M. Mackay, J. Tcheng, 2012, American Journal of Cardiovascular Drugs.

Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough.

J. Tcheng, 2006, Journal of interventional cardiology.

Clinical risk factors for ischemic complications after percutaneous coronary interventions: Results from the EPIC trial

R. Califf, E. Topol, S. Ellis, 1999 .

Coronary angioplasty performed with gradual and prolonged inflation using a perfusion balloon catheter: procedural success and restenosis rate.

E. Ohman, J. Tcheng, D. Kereiakes, 1992, American heart journal.

Clinical Trials Versus Clinical Practice: When Evidence and Practice Diverge--Should Nondiabetic Patients With 3-Vessel Disease and Stable Ischemic Heart Disease Be Preferentially Treated With CABG?

L. Klein, W. Weintraub, J. Tcheng, 2015, JACC. Cardiovascular interventions.

ACC/AHA 2013 Methodology for Developing Clinical Data Standards: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards

Eric E. Smith, R. Hendel, B. Bozkurt, 2014, Circulation.

Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited.

J. J. Griffin, G. Stone, C. Grines, 2005, American heart journal.

Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Block

David P Miller, R. Califf, E. Topol, 1998, Journal of the American College of Cardiology.

Local delivery of heparin post‐PTCA: A multicenter randomized pilot study

M. Krucoff, W. Cantor, J. Tcheng, 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention.

J. Tcheng, R. Stack, C. Green, 1998, The American journal of cardiology.

Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.

R. Califf, C. Buller, W. Cantor, 2002, JAMA.

Primary PCI In St-Elevation Myocardial Infarction

J. Tcheng, Sean P. Javaheri, 2010 .

Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction.

B. Gersh, G. Stone, C. Grines, 2006, American heart journal.

Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.

S. Murphy, J. Tcheng, D. Cohen, 2002, American heart journal.

Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention

R. Califf, P. Teirstein, E. Topol, 1999 .

Meta-analysis of Randomized Trials Acute ST-Segment Elevation Myocardial Infarction : A Abciximab as Adjunctive Therapy to Reperfusion in Correction

G. Stone, H. Suryapranata, J. Tcheng, 2005 .

Improved clinical outcomes with abciximab therapy in acute myocardial infarction: A systematic overview of randomized clinical trials

V. Hasselblad, R. Califf, G. Stone, 2003 .

Cost-Effectiveness of Coronary Stenting and Abciximab for Patients With Acute Myocardial Infarction: Results From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial

J. J. Griffin, G. Stone, C. Grines, 2003, Circulation.

Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.

R. Califf, E. Topol, A. Lincoff, 2002, The American journal of medicine.

Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin During Percutaneous Coronary Revascularization: Results From the EPILOG Randomized Trial

R. Califf, D. Mark, E. Topol, 2000, Circulation.

Long‐Term Protection from Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade with Percutaneous Coronary Intervention

David P Miller, R. Califf, E. Topol, 1998 .

Post-intervention cardiac enzyme elevations: Prognostic significance in IMPACT II

R. Califf, P. Teirstein, E. Topol, 1996 .

Pharmacodynamics and Pharmacokinetics of Higher-Dose, Double-Bolus Eptifibatide in Percutaneous Coronary Intervention

J. Tcheng, N. Kleiman, L. Jennings, 2001, Circulation.

Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.

J. J. Griffin, G. Stone, C. Grines, 2004, Journal of the American College of Cardiology.

Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial)

J. Carroll, G. Stone, C. Grines, 2003 .

Prasugrel: Clinical development and therapeutic application

J. Tcheng, D. Guerra, 2009, Advances in therapy.

(cadillac) trial abciximab and device investigation to lower late angioplasty complications primary percutaneous coronary intervention: Analysis from the controlled Impact of anemia in patients with acute myocardial infarction undergoing

C. Grines, R. Mehran, A. Lansky, 2011 .

Key references: Antiplatelet therapy as an adjunct to thrombolysis and coronary angioplasty

J. Tcheng, 2005, Journal of Thrombosis and Thrombolysis.

Eptifibatide in coronary intervention: past time for the next chapter.

J. Tcheng, M. Sherwood, 2015, Circulation. Cardiovascular interventions.

Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina

A. Kirtane, S. Murphy, J. Tcheng, 2006, Journal of Thrombosis and Thrombolysis.

Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet Glycoprotein IIb/IIIa Receptor Occupancy and Platelet Function: The Intracoronary Eptifibatide (ICE) Trial

J. Tcheng, C. Gibson, L. Jennings, 2010, Circulation.

Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

M. Josephson, G. Stone, C. Grines, 2004, Journal of the American College of Cardiology.

Eric E. Smith, G. Fonarow, K. Mahaffey, 2015, Journal of the American College of Cardiology.

Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.

J. Tcheng, J. Dery, K. Pieper, 2006, Journal of the American College of Cardiology.

Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction.

J. Tcheng, C. O’Shea, 1999, The Journal of invasive cardiology.

Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.

J. Tcheng, 1997, The American journal of cardiology.

Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents.

J. Tcheng, 1995, American heart journal.

Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?

J. Tcheng, M. Campbell, 2003, Journal of the American College of Cardiology.

Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions.

E. Topol, A. Lincoff, J. Tcheng, 2004, The American journal of cardiology.

Prospective analysis of possible myocardial damage or hemolysis occurring as a result of prolonged autoperfusion angioplasty in humans.

M. Krucoff, J. Muhlestein, J. Tcheng, 1992, Journal of the American College of Cardiology.

Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; Results from the ESPRIT trial

R. Harrington, J. Tcheng, C. Gibson, 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.

R. Califf, P. Teirstein, E. Topol, 1999, Journal of the American College of Cardiology.

Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.

R. Califf, P. Teirstein, A. Lincoff, 2003, Journal of interventional cardiology.

Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction.

J. J. Griffin, J. Carroll, G. Stone, 2005, The American journal of cardiology.

Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial).

J. J. Griffin, J. Carroll, G. Stone, 2003, The American journal of cardiology.

In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin.

G. Levine, J. Tcheng, D. Cohen, 2002, The American journal of cardiology.

Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy.

S. Murphy, J. Tcheng, D. Cohen, 2001, The American journal of cardiology.

Glycoprotein IIb/IIIa integrin blockade.

J. Tcheng, M. Madan, S. Berkowitz, 1998, Circulation.

Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction.

G. Stone, C. Grines, G. Dangas, 2009, Journal of interventional cardiology.

Stenting for acute myocardial infarction: The early United States multicenter experience

P. Teirstein, S. Steinhubl, E. Topol, 1996 .

ACC/AHA 2013 methodology for developing clinical data standards: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards.

Eric E. Smith, G. Fonarow, R. Hendel, 2014, Journal of the American College of Cardiology.

Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.

J. Tcheng, 2000, American heart journal.

Anatomic propensity for restenosis following coronary angioplasty

R. Califf, C. Nelson, J. Tcheng, 1991 .

Integrelin for emergency coronary artery stenting

P. Teirstein, E. Topol, J. Muhlestein, 1996 .

Modiﬁable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptiﬁbatide

R. Califf, E. Topol, A. Lincoff, 2016 .

Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.

J. Tcheng, M. Madan, S. Berkowitz, 2002, American heart journal.

Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy.

J. Tcheng, 1998, Texas Heart Institute journal.

Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.

R. Califf, P. Teirstein, E. Topol, 1997, The American journal of cardiology.

Appendix Participating Institutions , Principal Investigators , and Study Coordinators

R. Jordan, M. Effron, A. Lincoff, 2001 .

Unique device identifiers for coronary stent postmarket surveillance and research: A report from the Food and Drug Administration MedicalDeviceEpidemiologyNetworkUniqueDevice

Terrie L. Reed, J. Tcheng, K. Garratt, 2014 .

Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry.

J. Tcheng, Tracy Y. Wang, Alexander C. Fanaroff, 2019, American heart journal.

Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty.

B. Gersh, G. Stone, C. Grines, 2007, The American journal of cardiology.

Percutaneous transluminal coronary angioplasty in octogenarians as an effective therapy for angina pectoris.

R. Califf, C. Nelson, J. Tcheng, 1991, The American journal of cardiology.

Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).

J. J. Griffin, G. Stone, C. Grines, 2003, The American journal of cardiology.

Combined rotational and directional atherectomy guided by intravascular ultrasound in an occluded vein graft.

J. Tcheng, J. Hermiller, R. Stack, 1992, American heart journal.

Development of a new technique for reducing pressure pulse generation during 308-nm excimer laser coronary angioplasty.

L. Deckelbaum, J. Tcheng, H. Phillips, 1995, Catheterization and cardiovascular diagnosis.

Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).

J. J. Griffin, J. Carroll, G. Stone, 2005, The American journal of cardiology.

Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trial.

W. Cantor, J. Tcheng, D. Cohen, 2005, The Journal of invasive cardiology.

Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (the CADILLAC registry).

J. J. Griffin, G. Stone, C. Grines, 2005, The American journal of cardiology.

Point-of-care measurement of platelet function before angioplasty strongly predicts future target vessel revascularization

S. Steinhubl, J. Tcheng, D. Sane, 2002 .

Effects of 308 nanometer excimer laser energy on 316 L stainless-steel stents: implications for laser atherectomy of in-stent restenosis.

J. Tcheng, C. Reiser, J. O'shea, 2000, The Journal of invasive cardiology.

Coronary artery perforation during excimer laser coronary angioplasty. The percutaneous Excimer Laser Coronary Angioplasty Registry.

T. Ryan, S. Ellis, J. Isner, 1993, Journal of the American College of Cardiology.

Excimer laser coronary angioplasty: the New Approaches to Coronary Intervention (NACI) experience.

M. Leon, J. Isner, S. King, 1997, The American journal of cardiology.

Translating the Translation: What Clinicians Should Know About the Fourth Universal Definition of Myocardial Infarction.

J. Tcheng, C. Valentine, T. Waites, 2018, Journal of the American College of Cardiology.

Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention.

S. Denardo, J. Tcheng, P. R. Reid, 2003, The American journal of cardiology.

Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).

Brent A. Johnson, A. Tsiatis, J. Muhlestein, 2004, The American journal of cardiology.

Small-Molecule Glycoprotein IIb/IIIa Inhibitors as Adjunctive Therapy in Percutaneous Coronary Interventions

J. Tcheng, J. O'shea, 2000, Journal of Thrombosis and Thrombolysis.

Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).

R. Califf, E. Topol, A. Lincoff, 2002, The American journal of cardiology.

Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.

J. Tcheng, M. Madan, L. Jennings, 2001, American heart journal.

Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.

R. Califf, E. Topol, K. Anderson, 2000, American heart journal.

Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplasty

R. Califf, E. Topol, K. Anderson, 1993, Coronary artery disease.

Maximal benefit of integrelin platelet IIB/IIIa blockade 6–24 hours after therapy: Results of the IMPACT-II trial

R. Califf, E. Topol, A. Lincoff, 1996 .

Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor.

E. Ohman, A. Lincoff, R. Harrington, 1995, European heart journal.

An overview of the results of the EPIC trial.

R. Califf, E. Topol, A. Lincoff, 1995, European heart journal.

How important is time to treatment with primary percutaneous coronary intervention for acute myocardial infarction? Results from the CADILLAC trial

G. Stone, C. Grines, R. Mehran, 2003 .

Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion.

J. Tcheng, D. Zidar, David A. Zidar, 2009, JACC: Cardiovascular Interventions.

The effect of diabetes on restenosis

R. Califf, C. O'connor, C. Nelson, 1991 .

Importance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction

G. Stone, W. O’Neill, C. Grines, 2016 .

Complementarity of stenting and abciximab for percutaneous coronary intervention

K. Anderson, H. Weisman, M. Simoons, 1998 .

Clinical outcome of “high-risk” vs “elective” patients undergoing percutaneous coronary intervention: Results from IMPACT-II

R. Califf, E. Topol, A. Lincoff, 1996 .

A47 Differences in endpoint identification by investigators versus independent review

R. Califf, C. Granger, K. Mahaffey, 1996 .

Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial).

G. Stone, C. Grines, G. Weisz, 2004, The American journal of cardiology.

Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era.

J. Tcheng, R. Konstance, M. Sketch, 2004, Journal of interventional cardiology.

2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standar

Eric E. Smith, J. Fleg, M. Dake, 2012, Circulation.

Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial

G. Stone, C. Grines, S. Murphy, 2002 .

Relation between activated clotting time during angioplasty and abrupt closure.

R. Califf, C. Nelson, R. Harrington, 1996, Circulation.

Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

E. Antman, E. Topol, F. Van de Werf, 2005, JAMA.

Abstract Seventeenth annual meeting of the society for clinical trialP29 Prognostic significance of cardiac enzyme elevations detected through systematic screening in clinical trials

R. Califf, C. Granger, K. Mahaffey, 1996 .

Creation of pseudo narrowing during coronary angioplasty.

J. Tcheng, R. Stack, H. Phillips, 1991, The American journal of cardiology.

Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.

R. Califf, E. Topol, A. Lincoff, 1998, Journal of the American College of Cardiology.

Hemostasis of the femoral vasculature: Shouldn't we have an answer by now?

J. Tcheng, J. Pracyk, S. Drennan, 1999, American heart journal.

1002-82 Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction: The obesity paradox

G. Stone, C. Grines, R. Mehran, 2004 .

Restenosis after coronary angioplasty: an overview.

R. Califf, D. Mark, C. Nelson, 1991, Journal of the American College of Cardiology.

Multicenter registry of coronary atherectomy using the transluminal extraction-endarterectomy catheter

E. Ohman, W. O’Neill, C. Walker, 1990 .

Rebuttal: The CTO “No‐controversy” controversy: Should the field of CTO‐PCI be allowed to expand?

J. Tcheng, E. Jolicoeur, M. Patel, 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel

J. Tcheng, N. Kleiman, D. Moliterno, 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Outcomes following interventions in small coronary arteries with the use of hand-crimped Palmaz-Schatz stents.

L. Muhlbaier, J. Tcheng, R. Peter, 2000, The American journal of cardiology.

Association of pre-intervention activated clotting times (ACT) and clinical outcomes following percutaneous coronary revascularization: Results from the IMPACT-II trial

R. Califf, E. Topol, A. Lincoff, 1996 .

711-3-A Multicenter, Randomized, Double-Blind Pilot Trial of Standard Versus Low Dose Weight-Adjusted Heparin in Patients Treated with the Platelet GP IIb/IIIa Receptor Antibody c7E3 During Percutaneous Coronary Revascularization

R. Califf, P. Teirstein, E. Topol, 1995 .

Implementing a New Method for Activated Clotting Time:: Comparisons Between the Hemochron and the Actalyke-MaxACT Systems

J. Tcheng, M. Sketch, I. Welsby, 2003 .

Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications.

R. Califf, J. Tcheng, W. Hillegass, 2002, American heart journal.

Telehealth transformation: COVID-19 and the rise of virtual care

Jeffrey Ferranti, Blake Cameron, Eric G Poon, 2020, J. Am. Medical Informatics Assoc..

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.

J. Tcheng, 1996, The American journal of cardiology.

Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE Trial

M. Davidian, R. Califf, E. Ohman, 2002, Circulation.

Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.

J. J. Griffin, G. Stone, C. Grines, 2003, Journal of the American College of Cardiology.

Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes?

R. Califf, E. Peterson, W. Cantor, 2001, Journal of the American College of Cardiology.

Provisional stenting strategies: systematic overview and implications for clinical decision-making.

E. Peterson, W. Cantor, J. Tcheng, 2000, Journal of the American College of Cardiology.

Predicting the risk of abrupt vessel closure after angioplasty in an individual patient.

R. Califf, C. Nelson, J. Tcheng, 1994, Journal of the American College of Cardiology.

Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials

Akshay S. Desai, Brian J. McCourt, M. Landray, 2014 .

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.

J. J. Griffin, J. Carroll, G. Stone, 2002, The New England journal of medicine.

Clinical implications of vulnerable plaque.

J. Tcheng, J. Berger, J. Petersen, 2006, Future cardiology.

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.

David P Miller, V. Hasselblad, R. Califf, 1998, Circulation.

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

R. Califf, E. Topol, K. Anderson, 1994, The Lancet.

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.

E J Topol, R. Califf, E. Topol, 1994, Lancet.

Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.

R. Califf, E. Topol, M. Effron, 2000, The Annals of thoracic surgery.

Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions.

V. Hasselblad, R. Califf, E. Topol, 2003, The American journal of cardiology.

Acute complications of excimer laser coronary angioplasty: a detailed analysis of multicenter results. Coinvestigators of the U.S. and European Percutaneous Excimer Laser Coronary Angioplasty (PELCA) Registries.

E. Fleck, A. Baumbach, K. Karsch, 1994, Journal of the American College of Cardiology.

Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention

David P Miller, R. Califf, E. Topol, 1997 .

Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial).

G. Stone, C. Grines, R. Mehran, 2007, The American journal of cardiology.

Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade.

J. Tcheng, M. Mascelli, R. Maini, 2003, Developments in biologicals.

Multispecialty Enterprise Imaging Workgroup Consensus on Interactive Multimedia Reporting Current State and Road to the Future: HIMSS-SIIM Collaborative White Paper

James E. Tcheng, Alexander K. Goel, David A. Clunie, 2021, Journal of Digital Imaging.

Platelet Glycoprotein llb/llla

J. Tcheng, 2018 .

The new platelet inhibitors in coronary intervention

J. Tcheng, 1996 .

Section Review: Cardiovascular & Renal: Novel antiplatelet agents: The glycoprotein IIb/IIIa inhibitors

R. Harrington, J. Tcheng, B. S. Crenshaw, 1995 .

Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.

B. Gersh, G. Stone, W. O’Neill, 2005, Journal of the American College of Cardiology.

Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.

E. Topol, G. Stone, H. Suryapranata, 2006, Journal of the American College of Cardiology.

Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions.

J. Tcheng, P. Casterella, 2008, American Heart Journal.

After fibrinolysis: is cardiac catheterization the answer?

J. Tcheng, Kurt G. Kinney, 2006, Journal of the American College of Cardiology.

Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention.

R. Califf, E. Topol, K. Anderson, 2001, JAMA.

Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).

J. J. Griffin, G. Stone, C. Grines, 2004, The American journal of cardiology.

Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials

R. Califf, E. Topol, A. Lincoff, 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention.

Deepak L. Bhatt, R. Califf, E. Topol, 1998, American Journal of Cardiology.

Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial).

J. Tcheng, W. Owen, I. Sarembock, 2003, The American journal of cardiology.

Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox).

E. Topol, A. Lincoff, J. Tcheng, 2002, The American journal of cardiology.

Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. The Percutaneous Excimer Laser Coronary Angioplasty Registry.

S. Ellis, J. Tcheng, J. Bittl, 1992, The American journal of cardiology.

The natural history of single-vessel chronic coronary occlusion: a 25-year experience.

R. Califf, C. Nelson, J. Tcheng, 1997, American Heart Journal.

Percutaneous revascularization of chronic coronary occlusions: an overview.

R. Califf, R. Harrington, J. Tcheng, 1995, Journal of the American College of Cardiology.

Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial.

B. Gersh, G. Stone, C. Grines, 2004, American heart journal.

mpact of Anemia in Patients With cute Myocardial Infarction Undergoing rimary Percutaneous Coronary Intervention nalysis From the Controlled Abciximab and Device

J. J. Griffin, L. Grines, A. Lansky, 2016 .

Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).

Giulio Guagliumi, James E Tcheng, Gregg W Stone, 2006, The American journal of cardiology.

Vale, warfarin: a stentorian farewell.

J. Tcheng, D. Kong, 1999, American Heart Journal.

Anti-thrombotic management in interventional cardiology

J. Tcheng, S. Kindsvater, 2006 .

Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.

R. Califf, E. Topol, A. Lincoff, 2000, The American journal of cardiology.

Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide

R. Califf, E. Topol, A. Lincoff, 1998 .

Predictors of outcome of percutaneous excimer laser coronary angioplasty of saphenous vein bypass graft lesions. The Percutaneous Excimer Laser Coronary Angioplasty Registry.

B. Strauss, J. Isner, J. Tcheng, 1994, The American journal of cardiology.

The duke multicenter coronary transluminal extraction-endarterectomy registry: Acute and chronic results

W. O’Neill, C. Walker, J. Tcheng, 1991 .

Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial).

J. J. Griffin, G. Stone, W. O’Neill, 2004, The American journal of cardiology.

Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites.

Deepak L. Bhatt, L. Newby, A. Lincoff, 2008, The American journal of cardiology.

Safety of readministration of abciximab; interim results of the ReoPro readministration registry (R3)

R. Jordan, M. Effron, J. Tcheng, 1998 .

Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience.

R. Califf, E. Topol, J. Muhlestein, 1999, American heart journal.

Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome

R. Califf, E. Topol, A. Lincoff, 2000, Journal of the American College of Cardiology.

Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality.

Deepak L. Bhatt, E. Topol, V. Rajagopal, 2004, The American journal of cardiology.

Laser wire for crossing chronic total occlusions: "learning phase" results from the U.S. TOTAL trial. Total Occlusion Trial With Angioplasty by Using a Laser Wire.

M. Leon, J. Moses, J. Tcheng, 1998, Catheterization and cardiovascular diagnosis.

Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial

B. Davis, P. Fitzgerald, M. Savage, 2002, Circulation.

The changing profile of patient selection, procedural techniques, and outcomes in excimer laser coronary angioplasty. Participating Investigators of the Percutaneous Excimer Laser Coronary Angioplasty Registry.

J. Isner, J. Tcheng, J. Brinker, 1995, Journal of interventional cardiology.

Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).

V. Hasselblad, M. Krucoff, W. Cantor, 2003, The American journal of cardiology.

Hospital percutaneous coronary intervention volume and outcome: does it matter?

J. Tcheng, S. Kindsvater, 2005, Journal of interventional cardiology.

Coronary artery stents: Evaluating new designs for contemporary percutaneous intervention

James E Tcheng, D. Kandzari, J. Tcheng, 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards) and the American Society of Ec

Rebecca W Wilgus, N. Weissman, James D. Thomas, 2019, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory.

S. Solomon, R. Califf, C. O'connor, 2018, Journal of the American College of Cardiology.

Registry Assessment of Peripheral Interventional Devices Objective Performance Goals for Superficial Femoral and Popliteal Artery Peripheral Vascular Interventions.

Rebecca W Wilgus, M. Krucoff, D. Marinac-Dabic, 2020, Journal of vascular surgery.

Determining the Suitability of Registries for Embedding Clinical Trials in the United States: A Project of the Clinical Trials Transformation Initiative

Nicolle M Gatto, J Stephen Mikita, Jules Mitchel, 2020, Therapeutic Innovation & Regulatory Science.

Registry Assessment of Peripheral Interventional Devices (RAPID): Registry assessment of peripheral interventional devices core data elements.

Terrie L. Reed, Rebecca W Wilgus, M. Krucoff, 2018, Journal of vascular surgery.

Usability evaluation of a personal health record.

Noa Segall, James E Tcheng, K. Schulman, 2011, AMIA ... Annual Symposium proceedings. AMIA Symposium.

Detailed analysis of polymer response to delivery balloon expansion of drug-eluting stents versus bare metal stents.

C. Batich, S. Denardo, J. Tcheng, 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial

J. Carroll, G. Stone, C. Grines, 2001 .

ACCF/AHA 2011 Key Data Elements and Definitions of a Base Cardiovascular Vocabulary for Electronic Health Records: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards

Paul Heidenreich, James E. Tcheng, Robert C. Hendel, 2011, Circulation.

ACGME Interventional Cardiology Milestones 2.0–an overview: Endorsed by the Accreditation Council for Graduate Medical Education

C. Don, J. Tcheng, V. Arora, 2021, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).

J. Carroll, G. Stone, C. Grines, 2003, The American journal of cardiology.

Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet).

Terrie L. Reed, A. Kirtane, M. Krucoff, 2016, American heart journal.

Percutaneous coronary interventions and cardiovascular outcomes for patients with chronic total occlusions

L. Shaw, J. Tcheng, Y. Lokhnygina, 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial).

J. Piccini, G. Stone, M. Farkouh, 2012, The American journal of cardiology.

Novikoff hepatoma deoxyribonucleic acid polymerase. Sensitivity of the beta-polymerase to sulfhydryl blocking agents.

T. Kunkel, J. Tcheng, D. Stalker, 1976, Nucleic acids research.

Systematic review of current natural language processing methods and applications in cardiology

J. Pathak, J. Tcheng, D. Wright, 2021, Heart.

Treatment of Acute Infarction With PCI Outcomes of Optimal or “ Stent-Like ” Balloon Angioplasty in Acute Myocardial Infarction : The CADILLAC Trial

G. Stone, C. Grines, R. Mehran, 2016 .

Artificial Intelligence and Machine Learning in Cardiology.

J. Tcheng, R. Westcott, 2019, JACC. Cardiovascular interventions.

Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention

A. Abernethy, B. Hirsch, M. Krucoff, 2015, Journal of the American Heart Association.

ACCF/AHA 2011 key data elements and definitions of a base cardiovascular vocabulary for electronic health records: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards.

R. Hendel, A. Jacobs, P. Heidenreich, 2011, Journal of the American College of Cardiology.

Economic Analysis of Centralized vs. Decentralized Electronic Data Capture in Multi-Center Clinical Studies

Jose G. Conde, Ahmed Fadiel, Anita Walden, 2011, ITCH.

Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.

B. Gersh, G. Stone, C. Grines, 2005, Journal of the American College of Cardiology.

Adjunctive abciximab to reperfusion therapy in patients with acute st-segment elevation myocardial infarction: A meta-analysis of randomized trials

E. Antman, G. Stone, H. Suryapranata, 2005 .

Primary angioplasty in acute myocardial infarction

J. Tcheng, 2002 .

Short-term outcomes of balloon angioplasty versus stent placement for patients undergoing primary percutaneous coronary intervention: Implications for patients requiring early coronary artery bypass surgery.

James E Tcheng, Gregg W Stone, K. Harjai, 2013, American heart journal.

Outcomes following elective percutaneous coronary intervention without on-site surgical backup in a community hospital.

G. Stiles, J. Tcheng, M. Sketch, 2005, The American journal of cardiology.

Saline infusion in excimer laser coronary angioplasty.

J. Tcheng, J E Tcheng, 1996, Seminars in interventional cardiology : SIIC.

Unique device identifiers for coronary stent postmarket surveillance and research: a report from the Food and Drug Administration Medical Device Epidemiology Network Unique Device Identifier demonstration.

James E Tcheng, Jay Crowley, Terrie L. Reed, 2014, American heart journal.

DAMAGE TO POLYMER SURFACE AND DETACHMENT OF POLYMER FRAGMENTS DURING DELIVERY BALLOON EXPANSION OF DRUG-ELUTING STENTS: A PREVIOUSLY UNRECOGNIZED SOURCE FOR ADVERSE OUTCOMES

C. Batich, S. Denardo, J. Tcheng, 2012 .

Advancing medical device innovation through collaboration and coordination of structured data capture pilots: Report from the Medical Device Epidemiology Network (MDEpiNet) Specific, Measurable, Achievable, Results-Oriented, Time Bound (SMART) Think Tank.

Terrie L. Reed, M. Krucoff, D. Marinac-Dabic, 2017, Healthcare.

2016 ACC/ASE/ASNC/HRS/SCAI Health Policy Statement on Integrating the Healthcare Enterprise.

F. Resnic, W. Weintraub, J. Tcheng, 2016, Journal of the American College of Cardiology.

Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients

C. O'connor, S. Denardo, J. Tcheng, 2016, Circulation. Heart failure.

mpact of Diabetes Mellitus on Myocardial erfusion After Primary Angioplasty n Patients With Acute Myocardial Infarction

G. Stone, C. Grines, P. Zimetbaum, 2016 .

Cardiac Safety Research Consortium (CSRC): Cardiovascular Safety and Adverse Event Case Report Forms

E. Michelson, K. Mahaffey, N. Stockbridge, 2015, Therapeutic innovation & regulatory science.

Interventional cardiac catheterization at Duke Medical Center.

J C Greenfield, R. Califf, J. Greenfield, 1988, The American journal of cardiology.

J. Tcheng, C. Gibson, L. Jennings, 2010, Circulation.

Use of Aortic Counterpulsation to Improve Sustained Coronary Artery Patency During Acute Myocardial Infarction: Results of a Randomized Trial

R. Califf, M. Krucoff, M. Kern, 1994, Circulation.

Treatment of Palmaz-Schatz In-stent Restenosis: 6–Month Clinical Follow-up

H. Tan, J. Tcheng, R. Stack, 2000 .

Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.

R. Califf, E. Topol, S. Ellis, 1999, The New England journal of medicine.

Roadmap to a more useful and usable electronic health record

Ann L. Fruhling, Martina A. Clarke, A. Fruhling, 2021, Cardiovascular digital health journal.

Update on Abciximab Readministration During Percutaneous Coronary Interventions.

J. Tcheng, M. Madan, 2000, Current interventional cardiology reports.

Quantitative and Qualitative Comparison of Text-Based and Graphical User Interfaces for Computerized Provider Order Entry

James E. Tcheng, R. Clayton Musser, J. Tcheng, 2006, AMIA.

Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa.

J. Tcheng, J. O'shea, 1999, Expert opinion on investigational drugs.

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards

Eric E. Smith, G. Fonarow, R. Hendel, 2013 .

Eric E. Smith, K. Mahaffey, B. Chaitman, 2015, Circulation.

Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association

M. Relling, D. Roden, S. Shaw, 2016, Circulation. Cardiovascular genetics.

Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial

G. Stone, C. Grines, J. Moses, 2008, Catheterization and cardiovascular interventions.

Population Pharmacokinetics (PK) and Pharmacodynamics (PD) of Integrelin, a Platelet Aggregation Inhibitor

J. Tcheng, M. Kitt, T. Lorenz, 1996 .

Glycoprotein IIb/IIIa integrin blockade.

J. Tcheng, M. Madan, S. Berkowitz, 1998, Circulation.

Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa.

J. Tcheng, J. O'shea, O'shea, 1999, Expert opinion on investigational drugs.

Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention

P. Teirstein, S. Steinhubl, G. Dangas, 2001 .

Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC).

Eld, K. Rosen, M. Krucoff, 2015, Journal of the American College of Cardiology.

Cardiogenic Shock

W. Rogers, R. Russell, J. Tcheng, 2002, Contemporary Cardiology.

Artificial Intelligence, Computational Simulations, and Extended Reality in Cardiovascular Interventions.

F. Jaffer, F. Migliavacca, G. Dubini, 2023, JACC. Cardiovascular interventions.

E. Fleck, A. Baumbach, J. Tcheng, 1994, Journal of the American College of Cardiology.

B. Chaitman, A. Farb, G. Fonarow, 2015, Journal of the American College of Cardiology.

Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients

C. O'connor, S. Denardo, J. Tcheng, 2016, Circulation. Heart failure.